<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cy--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18182992</article-id><article-id pub-id-type="pmc">2361459</article-id><article-id pub-id-type="pii">6604148</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6604148</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Strasser</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Lutz</surname><given-names>T A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Maeder</surname><given-names>M T</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Thuerlimann</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bueche</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tsch&#x000f6;p</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kaufmann</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Holst</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Br&#x000e4;ndle</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>von Moos</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Demmer</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cerny</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Oncological Palliative Medicine, Division Oncology/Haematology, Department Internal Medicine and Palliative Care Center, Department of IMD, Cantonal Hospital</institution> Rorschacherstrasse, St Gallen 9007, <country>Switzerland</country></aff><aff id="aff2"><label>2</label><institution>Institute of Veterinary Physiology, Vetsuisse Faculty University of Zurich and Zurich Center of Integrative Human Physiology</institution> Winterthurerstrasse 260, Zurich 8057, <country>Switzerland</country></aff><aff id="aff3"><label>3</label><institution>Division of Cardiology, University Hospital</institution> Hebelstrasse 32, Basel 4031, <country>Switzerland</country></aff><aff id="aff4"><label>4</label><institution>Division Oncology/Haematology, Department Internal Medicine, Cantonal Hospital</institution> Rorschacherstrasse, St Gallen 9007, <country>Switzerland</country></aff><aff id="aff5"><label>5</label><institution>Department Psychiatry, Obesity Research Centre, University of Cincinnati &#x02013; Genome Research Institute</institution> 2180 East Galbraith Road, Cincinnati, OH 45237, <country>USA</country></aff><aff id="aff6"><label>6</label><institution>Laboratory for Molecular Pharmacology, The Panum Institute, University of Copenhagen</institution> Blegdamsvej 3, Copenhagen DK-2200, <country>Denmark</country></aff><aff id="aff7"><label>7</label><institution>Division of Endocrinology and Diabetes, Department Internal Medicine, Cantonal Hospital</institution> Rorschacherstrasse, St Gallen 9007, <country>Switzerland</country></aff><aff id="aff8"><label>8</label><institution>Division Oncology/Haematology, Department Internal Medicine, Cantonal Hospital</institution> Lo&#x000eb;strasse 170, Chur 7000, <country>Switzerland</country></aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:florian.strasser@kssg.ch">florian.strasser@kssg.ch</email><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:fstrasser@bluewin.ch">fstrasser@bluewin.ch</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>01</month><year>2008</year></pub-date><pub-date pub-type="collection"><day>22</day><month>01</month><year>2008</year></pub-date><pub-date pub-type="ppub"><day>29</day><month>01</month><year>2008</year></pub-date><volume>98</volume><issue>2</issue><fpage>300</fpage><lpage>308</lpage><history><date date-type="received"><day>13</day><month>08</month><year>2007</year></date><date date-type="rev-recd"><day>02</day><month>11</month><year>2007</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2007</year></date></history><copyright-statement>Copyright 2008, Cancer Research UK</copyright-statement><copyright-year>2008</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>Twenty-one adult patients were randomised to receive ghrelin on days 1 and 8 and placebo on days 4 and 11 or vice versa, given intravenously over a 60-min period before lunch: 10 received 2&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup> (lower-dose) ghrelin; 11 received 8&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup> (upper-dose) ghrelin. Active and total ghrelin, growth hormone (GH), and insulin-like growth factor 1 levels were monitored at baseline (4&#x02013;5 days before day 1), during treatment days, and at end of study (day 17/18). Drug-related adverse events (assessed by NCI-CTC-toxicity criteria and cardiac examination) did not differ between ghrelin and placebo. No grade 3/4 toxicity or stimulation of tumour growth was observed. The peak increase of GH, a biological marker of ghrelin action, was 25&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup> with lower-dose and 42&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup> with upper-dose ghrelin. Morning fasting total ghrelin levels were higher (<italic>P</italic>&#x0003c;0.05) for upper-dose patients at end of study (3580&#x02009;pg&#x02009;ml<sup>&#x02212;1</sup>) than at baseline (990&#x02009;pg&#x02009;ml<sup>&#x02212;1</sup>). Insulin-like growth factor 1 levels did not change. At day 8, 81&#x00025; of patients preferred ghrelin to placebo as against 63&#x00025; at the end of study. Nutritional intake and eating-related symptoms, measured to explore preliminary efficacy, did not differ between ghrelin and placebo. Ghrelin is well tolerated and safe in patients with advanced cancer. For safety, tolerance, and patients' preference for treatment, no difference was observed between the lower- and upper-dose group.</p></abstract><kwd-group><kwd>cachexia</kwd><kwd>anorexia</kwd><kwd>ghrelin</kwd><kwd>nutrition</kwd></kwd-group></article-meta></front><body><p>Cancer patients often suffer from cancer anorexia/cachexia syndromes (CACS) and the consequences &#x02013; fatigue, weakness, decreased performance status, poor tolerance of antineoplastic interventions, and psychosocial distress. Cancer anorexia/cachexia syndromes are characterised by a catabolic state triggered by tumour by-products, proinflammatory cytokines, and mediators of the neurohormonal system, causing loss of muscle and fat mass, anorexia, gastrointestinal dysmotility and early satiety, decreased anabolic drive, and hypermetabolism (<xref ref-type="other" rid="bib27">Inui, 2002</xref>).</p><p>There are few pharmacological treatment options for CACS, but it has been shown that this patient population with advanced cancer has the capacity to respond to appetite stimulation therapy (<xref ref-type="other" rid="bib62">Yavuzsen <italic>et al</italic>, 2005</xref>).</p><p>Ghrelin, an endogenous ligand for the growth hormone (GH) secretagogue receptor, displays dose-dependent GH-releasing activity (<xref ref-type="other" rid="bib30">Kojima <italic>et al</italic>, 1999</xref>). Ghrelin, which is predominantly secreted by gastric endocrine cells, stimulates food intake and triggers a positive energy balance through a central mechanism involving hypothalamic neuropeptides. In preclinical cachexia models, ghrelin has had stimulatory effects on appetite and food intake (<xref ref-type="other" rid="bib23">Hanada <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib58">Wang <italic>et al</italic>, 2006</xref>), lean body mass (<xref ref-type="other" rid="bib10">DeBoer <italic>et al</italic>, 2007</xref>), gastrointestinal motility (<xref ref-type="other" rid="bib9">Date <italic>et al</italic>, 2002</xref>), energy metabolism, and proinflammatory cytokine expression (<xref ref-type="other" rid="bib12">Dixit <italic>et al</italic>, 2004</xref>), and it has also alleviated cancer chemotherapy-associated dyspepsia (<xref ref-type="other" rid="bib36">Liu <italic>et al</italic>, 2006</xref>) and vomiting (<xref ref-type="other" rid="bib49">Rudd <italic>et al</italic>, 2006</xref>). These experimentally induced cancer models provide promising but not sufficient evidence for an effect of ghrelin in human cancer, prompting clinical studies in a representative clinical population, including long-term studies in humans.</p><p>In human volunteers, intravenous (i.v.) (<xref ref-type="other" rid="bib43">Nagaya <italic>et al</italic>, 2001a</xref>; <xref ref-type="other" rid="bib61">Wren <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib2">Akamizu <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib50">Schmid <italic>et al</italic>, 2005</xref>; <xref ref-type="other" rid="bib35">Levin <italic>et al</italic>, 2006</xref>) or subcutaneous (<xref ref-type="other" rid="bib17">Enomoto <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib14">Druce <italic>et al</italic>, 2006</xref>) ghrelin showed safety and tolerability at dosages up to 10&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup> &#x02013; sufficient to promote orexigenic, prokinetic, and GH-releasing effects; in those studies, a sensation of warmth, sleepiness, bowel movements, and hunger were reported. Comparable results with i.v. ghrelin (single-dose bolus, daily for 3 weeks, or i.v. infusion) were reported in patients with chronic heart failure (<xref ref-type="other" rid="bib44">Nagaya <italic>et al</italic>, 2001b</xref>, <xref ref-type="other" rid="bib45">2004</xref>), COPD (<xref ref-type="other" rid="bib42">Nagaya <italic>et al</italic>, 2005</xref>), or diabetic gastroparesis (<xref ref-type="other" rid="bib41">Murray <italic>et al</italic>, 2005</xref>).</p><p>In melanoma-bearing nude mice, ghrelin plasma concentration increased with cachexia progression (<xref ref-type="other" rid="bib22">Hanada <italic>et al</italic>, 2004</xref>). In cancer patients with cachexia (various cancers, <italic>n</italic>=21 (<xref ref-type="other" rid="bib20">Garcia <italic>et al</italic>, 2005</xref>); breast and colorectal cancer, <italic>n</italic>=18 (<xref ref-type="other" rid="bib60">Wolf <italic>et al</italic>, 2006</xref>); lung cancer, <italic>n</italic>=21 (<xref ref-type="other" rid="bib51">Shimizu <italic>et al</italic>, 2003</xref>)), ghrelin morning fasting levels were 1.3- to 1.5-fold higher than in those without cachexia and healthy controls. In contrast, ghrelin levels were normal in subgroups of patients in one study (39&#x00025;) (<xref ref-type="other" rid="bib60">Wolf <italic>et al</italic>, 2006</xref>) and all patients in another study (gastric and colorectal cancer, <italic>n</italic>=58) (<xref ref-type="other" rid="bib25">Huang <italic>et al</italic>, 2007</xref>). Lower ghrelin values in patients with colorectal cancer (<italic>n</italic>=29) than in healthy controls (<italic>n</italic>=50) were also reported (<xref ref-type="other" rid="bib13">D'Onghia <italic>et al</italic>, 2007</xref>). Preliminary findings suggest that pharmacological doses of ghrelin alleviate cancer cachexia. Tumour-bearing mice showed improved food intake and body composition only at a high intraperitoneal dose (40&#x02009;<italic>&#x003bc;</italic>g&#x02009;day<sup>&#x02212;1</sup>) of ghrelin (<xref ref-type="other" rid="bib58">Wang <italic>et al</italic>, 2006</xref>). In one pilot study, seven cancer patients had 31&#x00025; higher energy intake with i.v. ghrelin than with placebo (5&#x02009;pmol&#x02009;kg<sup>&#x02212;1</sup>&#x02009;min<sup>&#x02212;1</sup> for 180&#x02009;min equals 3&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup>), with no adverse effects (<xref ref-type="other" rid="bib46">Neary <italic>et al</italic>, 2004</xref>).</p><p>This trial was conducted to assess safety, tolerability, and pharmacokinetics in a 2-week trial of ghrelin infusion given intravenously, at one of two dose levels, once weekly, 1&#x02009;h before lunch, to patients with far-advanced, incurable cancer, and involuntary loss of weight and appetite.</p><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><p>This single-centre, randomised, double-blind, placebo-controlled, two-arm, double-crossover study adhered to Good Clinical Practice (GCP) and the Declaration of Helsinki and was approved by the local Ethical Review Board and Health Authorities.</p><sec><title>Participants</title><p>Physicians at the Kantonsspital in St Gallen, Switzerland recruited adult patients with advanced incurable cancer who had loss of appetite (&#x02a7e;3 visual analogue scale (VAS; 0=best, 10=worst)) and a weight loss of &#x02a7e;2&#x00025; within 2 or &#x02a7e;5&#x00025; within 6 months before the study not related to recent surgery.</p><p>Eligible patients gave written informed consent to participate, were able to eat without assistance, did not receive enteral or parenteral nutrition, and had no significant causes of secondary anorexia (defined as no severe symptoms or complications of the gastrointestinal tract impeding oral food intake) (<xref ref-type="other" rid="bib48">Omlin and Strasser, 2007</xref>), as ensured by pre-baseline palliative oncology assessments. Patients were expected not to require new systemic antineoplastic treatment for the total study period of 3 weeks; those with unchanged continuous or weekly treatment for at least 2 months were eligible. Concomitant medication was to remain unchanged for at least 1 week before baseline. One patient having octreotide treatment was removed from analysis.</p></sec><sec><title>Intervention</title><p>In a randomised, double-blind, placebo-controlled, double-crossover trial, 4&#x02013;5 days after baseline, patients received ghrelin on days 1 and 8 and placebo on days 4 and 11 or vice versa; end of study was day 17/18 (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>On treatment days, patients ingested only water from midnight to breakfast. In the outpatient clinic, safety laboratory values and fasting hormone blood samples (including testosterone in male patients) were drawn at 0800 hours; venous access was maintained for pharmacokinetics. Patients received a standardised breakfast (120&#x02009;g bread, 20&#x02009;g butter, 60&#x02009;g jam, 200&#x02009;ml coffee with milk). At 1000 hours, a second i.v. line was inserted in the other arm for treatment given from 1030 to 1130 hours. Immediately after the end of the infusion, patients walked for approximately 5&#x02009;min the 90&#x02009;m to the restaurant where they received priority serving, starting the meal within 5&#x02009;min. A hospital volunteer accompanied the patients and documented the conditions (i.e., quality of service, quiet atmosphere) at lunch. Following evaluations performed after lunch, all patients, except one inpatient, returned home.</p><p>Ghrelin of Good Manufacturing Practice quality was purchased from Clinalfa (Merck Biosciences, Switzerland) as vials of 88&#x02009;<italic>&#x003bc;</italic>g, stored at &#x02212;20&#x000b0;C, and dissolved in 250&#x02009;ml normal saline by the hospital pharmacy immediately before application. The treatment was titrated up within the first 10&#x02009;min (20&#x00025; increase each 2&#x02009;min) and maintained for the next 50&#x02009;min. The lower-dose group (LD) received 10&#x02009;pmol&#x02009;kg<sup>&#x02212;1</sup>&#x02009;min<sup>&#x02212;1</sup> (equals 0.0336&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup>&#x02009;min<sup>&#x02212;1</sup>, approximately 2&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup>). The dose was based on the reported maximal GH stimulation in human volunteers (<xref ref-type="other" rid="bib61">Wren <italic>et al</italic>, 2001</xref>) and multiplied by 2 to account for suspected ghrelin resistance (<xref ref-type="other" rid="bib51">Shimizu <italic>et al</italic>, 2003</xref>). After observing treatment tolerance in the LD patients, we administered the upper-dose group (UD) 40&#x02009;pmol&#x02009;kg<sup>&#x02212;1</sup>&#x02009;min<sup>&#x02212;1</sup> (approximately 8&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup>). Normal saline was used as placebo.</p></sec><sec><title>Objectives</title><p>We tested the safety and tolerability of two dose levels of i.v. ghrelin in patients with far-advanced cancer based on toxicity, tumour measurements, and patients' perceived tolerance. We also assessed the pharmacokinetics.</p></sec><sec><title>Outcome measures</title><p>Patients were assessed at each visit by using the NCI-CTC toxicity criteria Version 3.0, including standard blood examinations (hematology, chemistry panels), and cardiology evaluations, including echocardiography at baseline and at end of study. During the treatment phase, research personnel regularly contacted patients at home during the daytime to check for their safety. Before each infusion for each patient, the responsible investigator reviewed treatment logs for the preceding infusions and the results of the morning laboratory examinations. On study day 7 and at end of study, patients were asked about their perception of their tolerance and preference of day 1 (and 7) <italic>vs</italic> day 4 (and 11) treatments. Radiological measurements were made within 2 weeks before the first infusion and within 2 weeks after the last infusion by CT-scans, except for two patients with liver metastasis who had once an ultrasound (no. 11) or an MRI (no. 18), for one patient monitored only by ultrasound (no. 11) or once at study end (no. 4), one patient who had a prior MRI liver metastasis monitored by ultrasound, and one patient who had an ultrasound of the liver. An independent radiologist reviewed all films made before baseline, at baseline, and at end of study to judge tumour size and dynamics.</p><p>Patients' nutritional intake was monitored daily. At baseline, dieticians assessed patients' food preferences, reviewed the procedures and meals for the next 2 weeks, and distributed a food scale and standard protocols for prospective &#x02018;third-person' (family members of patients) assessments (<xref ref-type="other" rid="bib6">Bruera <italic>et al</italic>, 1986</xref>). A trained volunteer accompanied patients at lunch in a designated quiet section of the hospital restaurant. Meals were photographed and kitchen personnel documented the weight of each meal component before and after each patient ate it.</p><p>To detect acute symptom effects of treatment, VAS assessments (0=best, 10=worst) of appetite, hunger, anxiety, early satiety, nausea, and fatigue were measured before, during, and after infusion. Immediately after lunch on treatment days, VAS assessments of the pleasantness of the meal, perceived appetite, and perception of amount of food intake were obtained.</p><p>For ghrelin assays, 5&#x02009;ml blood was collected in a precooled EDTA vacutainer tube containing aprotinin (33&#x02009;kIU), placed immediately on ice, and centrifuged (4&#x000b0;C, 3000&#x02009;G, 5&#x02009;min). For each millilitre of plasma, 10&#x02009;<italic>&#x003bc;</italic>l PMSF-Isopropanol, 50&#x02009;<italic>&#x003bc;</italic>l 1N-HCL, and 50&#x02009;<italic>&#x003bc;</italic>l aprotinin were added, and aliquots were stored at &#x02212;80&#x000b0;C until batch analysis. Serum was collected and cooled for GH, insulin-like growth factor 1 (IGF-1), interleukin-6 (IL-6), and leptin analysis. Testosterone radioimmunoassays (Diagnostic Products Corporation; B&#x000fc;hlmann, Salzburg, Austria) were performed from serum sent to routine safety labs. The radioimmunoassay kits used for total and active ghrelin were from Linco Research (St Charles, MO, USA); for GH (active GH IRMA immunoradiometric assay) from Diagnostic Systems Laboratory (Webster, TX, USA); for IGF-1 (human, bovine) from Peninsula Laboratories (San Carlos, CA, USA); for IL-6 (Quantikine human ELISA) from R&#x00026;D Systems (Minneapolis, MN, USA); and for leptin (human RIA) from Millipore (Billerica, MA, USA).</p><p>Autonomic dysfunction was assessed as described previously (<xref ref-type="other" rid="bib53">Strasser <italic>et al</italic>, 2006</xref>). Standard deviation of beat-to-beat intervals (SDNN) was analysed at baseline and at end of study for 20&#x02009;min in both the LD and UD; and in the UD, in addition, 30&#x02009;min before infusion until after lunch on treatment days.</p></sec><sec><title>Sample size</title><p>Safety and tolerability was assessed on the basis of a sample size of 10 patients per dose level.</p></sec><sec><title>Treatment assignment, randomisation, and blinding</title><p>Patients were randomised by independent personnel at the hospital pharmacy, where the random allocation sequence produced (switches after 1 to maximal 3 patients) was assigned and the sealed envelopes for each patient distributed. A master randomisation list was kept in a locked container at the pharmacy. Copies of the documents in each sealed envelope were stored in a locked container accessible to clinicians for emergencies, as required by GCP standards.</p><p>Less than 30&#x02009;min before each infusion, the pharmacy produced identical bags containing indistinguishable liquids of 250&#x02009;ml normal saline with or without ghrelin.</p><p>The database was closed after completion of the study and rating of all adverse events. Thereafter, an independent senior physician who had controlled the randomisation procedure, the master randomisation list, and the broken envelopes revealed the treatment assignments.</p></sec><sec><title>Statistical analyses</title><p>All analyses were performed with SPSS (Version 11.5). Descriptive statistics were used for demographic and baseline variables, frequencies of adverse events, and tumour measurements. For exploratory analyses of patients' preference of treatment, we used the exact binominal test. For pharmacokinetics (GH, ghrelin), glucose values, IGF-1 levels, nutritional intake, and SDNN, a comparison was made between changes from baseline for each individual subject between the two interventions (sum of two ghrelin periods <italic>vs</italic> sum of two placebo periods). For between-patient comparison of peak GH (median), the Wilcoxon's (no-signed) rank sum test (Mann&#x02013;Whitney) was used; and for within-patient comparisons (ghrelin morning fasting levels 3 days after the prior ghrelin infusion, glucose, IGF-1, nutritional intake, and SDNN) the Wilcoxon's signed rank test was used.</p></sec></sec><sec><title>RESULTS</title><p>Flow (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and demographics (<xref rid="tbl1" ref-type="table">Table 1</xref>) for the 20 patients studied were recorded. Oral intake at the fixed breakfast at treatment days was 296&#x02009;kcal (stable disease (SD) 80) in LD and 276&#x02009;kcal (118) in UD; one patient in LD and five in UD eat less than 250&#x02009;kcal. Most patients (17 of 20) had ongoing inflammation (C-reactive protein (CRP) &#x0003e;10&#x02009;mg&#x02009;ml<sup>&#x02212;1</sup>) (<xref ref-type="other" rid="bib18">Fearon <italic>et al</italic>, 2006</xref>). Creatinine was 83&#x02009;<italic>&#x003bc;</italic>mol&#x02009;l<sup>&#x02212;1</sup> (mean, SD 31) in LD and 73&#x02009;<italic>&#x003bc;</italic>mol&#x02009;l<sup>&#x02212;1</sup> (17) in UD and one patient each in LD and UP had a value above normal (&#x0003c;105&#x02009;<italic>&#x003bc;</italic>mol&#x02009;l<sup>&#x02212;1</sup>). No patient had malignant gastroparesis. Two patients stopped study treatment early in the second week because of malignant bowel obstruction and blood-culture positive infection, respectively. Treatment of one patient was unblinded during the study because of apoplectiform deafness.</p><p>Concomitant pre-existing medications included laxatives (76&#x00025;), opioids (67&#x00025;), propulsive drugs (67&#x00025;), antacids (62&#x00025;), vitamins (57&#x00025;), and many others. Three patients (upper dose only) were on unchanged treatment for &#x0003e;1 week with megestrol acetate (160&#x02009;mg twice daily) and three different patients on intramuscular testosterone, and one patient each received fish oil (500&#x02009;mg twice daily) or dexamethasone (8&#x02009;mg&#x02009;day<sup>&#x02212;1</sup>). Six patients (29&#x00025;) received anticancer agents before and during the study (three gemcitabine; one each irinotecan, vinblastine, or bevacizumab). One patient was started on dexamethasone (4&#x02009;mg twice daily) for liver capsule pain on day 14.</p><p>Of 205 adverse events, 49 possibly and 9 probably were related to an agent studied &#x02013; placebo as well as ghrelin (<xref rid="tbl2" ref-type="table">Table 2</xref>). They included abnormal liver tests or low potassium (three patients on ghrelin, four on placebo); increased serum amylase, creatinine, and D-dimer (seven on placebo); and increased CRP (two on ghrelin). Blinded clinicians rated the other adverse events as unrelated or probably unrelated to treatment. Those were cardiac arrhythmia during LD ghrelin infusion; constipation or infection with UD ghrelin; sinus tachycardia, pulmonary rales, increased stool frequency, or back pain with LD placebo; and blurred vision with UD placebo. Body temperature and oxygen saturation remained unchanged during and after the infusion of ghrelin and placebo in both dosage groups. Of 13 serious adverse events, one &#x02013; transient apoplectiform deafness on day 13 &#x02013; was judged as probably related to treatment on day 11 (placebo).</p><p>The mean scores for tolerability of the study medication immediately after infusion and after lunch did not differ between ghrelin and placebo or between LD and UD. More patients preferred ghrelin to placebo (<xref rid="tbl3" ref-type="table">Table 3</xref>) at day 7 and at end of study, with no evidence of patients' awareness of their treatment assignment.</p><p>During the study period, two patients experienced progressive disease (PD). Before enrolment, one had had SD and one, PD. Of 16 patients with SD during the study period, 10 had PD, five had SD, and one had partial response before enrolment. Of two patients who stopped study treatment early, one had SD and one had PD at enrolment. The mean time interval between tumour assessments pre-baseline and at baseline was 79 days in LD and 29 days in UD, and between assessments at baseline and after the study was 34 and 25 days, respectively.</p><p>For total ghrelin, in the UD, elevated morning fasting levels were observed 3 days after the prior ghrelin infusion compared to after placebo (<italic>P</italic>&#x0003c;0.001), as confirmed by an independent, blinded laboratory (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>The mean differences of the peak GH levels (of week 1 and week 2) compared to baseline were higher in UD (50&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup> (SD 20)) than in LD (28&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup> (6)) (<italic>P</italic>=0.004).</p><p>In one patient (UD) having gastrectomy 6 months before baseline, neither substantial differences in baseline values nor peak levels of active or total ghrelin or GH were detected.</p><p>Insulin-like growth factor 1 did not increase at day 17/18 as compared to study start in any patient examined (maximal increase from baseline was 170&#x00025;); mean IGF-1 was 1359&#x02009;pg per 100&#x02009;<italic>&#x003bc;</italic>l (&#x000b1;994) in LD (<italic>n</italic>=7) and 1096&#x02009;pg per 100&#x02009;<italic>&#x003bc;</italic>l (&#x000b1;495) in UD (<italic>n</italic>=9), and mean change from baseline &#x02212;2624&#x02009;pg per 100&#x02009;<italic>&#x003bc;</italic>l (&#x000b1;2888) and &#x02212;624&#x02009;pg per 100&#x02009;<italic>&#x003bc;</italic>l (&#x000b1;962) (<italic>P</italic>=0.055).</p><p>During treatment days, blood glucose values compared to baseline after infusions were higher when patients received ghrelin than when receiving placebo in LD only after lunch (3.6 <italic>vs</italic> 2.5&#x02009;mmol&#x02009;l<sup>&#x02212;1</sup> (<italic>P</italic>=0.005)) but not after infusion (1.5 <italic>vs</italic> 1.3&#x02009;mmol&#x02009;l<sup>&#x02212;1</sup>, <italic>P</italic>=0.16), in UD both after lunch (2.4 <italic>vs</italic> 1.3&#x02009;mmol&#x02009;l<sup>&#x02212;1</sup> (<italic>P</italic>=0.01)) and after infusion (0.8 <italic>vs</italic> 0.2&#x02009;mmol&#x02009;l<sup>&#x02212;1</sup> (<italic>P</italic>=0.044)).</p><p>Plasma levels of IL-6 did not change throughout the treatment period (results not shown).</p><p>There were no significant differences in nutritional intake or symptoms compared to baseline when patients received ghrelin or placebo. Nutritional-intake-at-lunch compared to baseline was in LD &#x02212;105&#x02009;kcal with ghrelin and &#x02212;17&#x02009;kcal with placebo, in UD 251 and 230&#x02009;kcal, respectively; nutritional-intake-at-lunch-and-rest-of-the-day was (LD) 145 and 228&#x02009;kcal, and (UD) 244 and 156&#x02009;kcal, respectively (all <italic>P</italic>=NS). In UD patients not receiving concurrent chemotherapy (<italic>n</italic>=8), a trend towards increased differences compared to baseline for nutritional-intake-at-lunch-and-rest-of-the-day (ghrelin: 448&#x02009;kcal; placebo: 128&#x02009;kcal; <italic>P</italic>=0.093) but not nutritional-intake-at-lunch (ghrelin: 330&#x02009;kcal; placebo: 200&#x02009;kcal; <italic>P</italic>=ns) was observed.</p><p>Mean SDNN was 57&#x000b1;28&#x02009;ms at baseline and 73&#x000b1;57&#x02009;ms at end of study in 18 evaluable patients (<italic>P</italic>=ns); in UD (<italic>n</italic>=9), for ghrelin 84&#x000b1;40&#x02009;ms and for placebo 78&#x000b1;35&#x02009;ms in week 1 (<italic>P</italic>=NS), and in week 2, 75&#x000b1;35 and 80&#x000b1;27&#x02009;ms (<italic>P</italic>=NS), respectively.</p></sec><sec><title>DISCUSSION</title><p>This is, to our knowledge, the first trial investigating two doses of ghrelin in patients with advanced cancer and anorexia/cachexia. Intravenous ghrelin infusion for 60&#x02009;min at 2 or 8&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup> body weight is well tolerated and safe in these patients who represent a &#x02018;real world' population of cancer patients with anorexia/cachexia.</p><p>At present, no dose-limiting toxicity has been reported for ghrelin in animals or humans. The dosage used was based on the reported maximal GH stimulation in human volunteers (<xref ref-type="other" rid="bib61">Wren <italic>et al</italic>, 2001</xref>) and on prior trials using up to 10&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup> in healthy volunteers and 6&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup> in patients (<xref ref-type="other" rid="bib44">Nagaya <italic>et al</italic>, 2001b</xref>). Our data suggest a dose relationship with GH stimulation. In cachectic tumour-bearing mice (MCG101), higher ghrelin doses were required to increase food intake and body weight than in control mice (<xref ref-type="other" rid="bib58">Wang <italic>et al</italic>, 2006</xref>). Other interventional CACS studies did not compare ghrelin doses (<xref ref-type="other" rid="bib23">Hanada <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib46">Neary <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib10">DeBoer <italic>et al</italic>, 2007</xref>).</p><p>Morning fasting levels of ghrelin in patients (<xref ref-type="other" rid="bib51">Shimizu <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib20">Garcia <italic>et al</italic>, 2005</xref>; <xref ref-type="other" rid="bib60">Wolf <italic>et al</italic>, 2006</xref>; <xref ref-type="other" rid="bib25">Huang <italic>et al</italic>, 2007</xref>) or animals (<xref ref-type="other" rid="bib22">Hanada <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib36">Liu <italic>et al</italic>, 2006</xref>) with CACS are still poorly understood. In animals, both higher (<xref ref-type="other" rid="bib22">Hanada <italic>et al</italic>, 2004</xref>) and lower (<xref ref-type="other" rid="bib36">Liu <italic>et al</italic>, 2006</xref>) ghrelin levels than controls are reported. Several studies showed higher ghrelin levels (<xref ref-type="other" rid="bib51">Shimizu <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib20">Garcia <italic>et al</italic>, 2005</xref>) or higher levels only in subgroups (61&#x00025; of 18 breast and colorectal cancer patients) (<xref ref-type="other" rid="bib60">Wolf <italic>et al</italic>, 2006</xref>) in patients with CACS as compared to non-cachetic cancer patients or healthy controls; however, normal (<xref ref-type="other" rid="bib25">Huang <italic>et al</italic>, 2007</xref>) ghrelin levels were reported as well. The differences of fasting levels of ghrelin in cancer patients may be explained by differences in BMIs, 20.7&#x02009;kg&#x02009;m<sup>&#x02212;2</sup> in LD and 20.6&#x02009;kg&#x02009;m<sup>&#x02212;2</sup> in UD, and 18.5&#x02009;kg&#x02009;m<sup>&#x02212;2</sup> in others (<xref ref-type="other" rid="bib51">Shimizu <italic>et al</italic>, 2003</xref>). It remains unclear whether ghrelin plasma levels are increased in cancer patients and whether high plasma levels of ghrelin will induce resistance to ghrelin. It remains to be clearly shown whether the response to peripheral ghrelin differs depending on the prevailing ghrelin level.</p><p>In transgenic mice overexpressing ghrelin, the acute stimulation of food intake of exogenous ghrelin was not diminished (<xref ref-type="other" rid="bib59">Wei <italic>et al</italic>, 2006</xref>). In patients with anorexia nervosa, in whom chronic hyperghrelinaemia presents with two- to three-fold increased levels (<xref ref-type="other" rid="bib5">Broglio <italic>et al</italic>, 2004</xref>), i.v. ghrelin (1&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup> per hour for 5&#x02009;h (5&#x02009;pmol&#x02009;kg<sup>&#x02212;1</sup>&#x02009;min<sup>&#x02212;1</sup> &#x000d7; 300&#x02009;min; <xref ref-type="other" rid="bib38">Miljic <italic>et al</italic>, 2006</xref>) or 1&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup> (<xref ref-type="other" rid="bib5">Broglio <italic>et al</italic>, 2004</xref>)) caused much lower GH and glucose increases than in healthy volunteers and caused no appetite stimulation but increased sleepiness. In two patients having ghrelin-producing tumours in gastro-entero-pancreatic system (<xref ref-type="other" rid="bib8">Corbetta <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib57">Tsolakis <italic>et al</italic>, 2004</xref>), BMI remained high and the appetite good despite failure to respond to anticancer treatment.</p><p>In our study, we observed no major unexpected tumour-growth dynamics, but the study design with short intervals of the tumour measurements impedes firm conclusions. As ghrelin is also a potent GH secretagogue, there are concerns about GH-mediated stimulation of tumour growth, especially regarding treatment of cancer patients. Several cell lines express the ghrelin receptor (<xref ref-type="other" rid="bib63">Yeh <italic>et al</italic>, 2005</xref>; <xref ref-type="other" rid="bib16">Ekeblad <italic>et al</italic>, 2006</xref>) and secrete ghrelin (<xref ref-type="other" rid="bib63">Yeh <italic>et al</italic>, 2005</xref>). <italic>In vitro</italic> studies suggest that ghrelin may enhance the proliferation of prostate (<xref ref-type="other" rid="bib63">Yeh <italic>et al</italic>, 2005</xref>) and pancreatic (<xref ref-type="other" rid="bib15">Duxbury <italic>et al</italic>, 2003</xref>) cancer cells, but not of a lung cancer cell line, where it induced dose-dependent inhibition of cell proliferation and increased apoptosis (<xref ref-type="other" rid="bib7">Cassoni <italic>et al</italic>, 2006</xref>). Some tumours from archival samples express ghrelin (<xref ref-type="other" rid="bib29">Jeffery <italic>et al</italic>, 2005</xref>), whereas others do not (<xref ref-type="other" rid="bib7">Cassoni <italic>et al</italic>, 2006</xref>; <xref ref-type="other" rid="bib39">Mottershead <italic>et al</italic>, 2007</xref>). Tumour incidence is not increased in patients with anorexia nervosa (<xref ref-type="other" rid="bib37">Mellemkjaer <italic>et al</italic>, 2001</xref>) despite elevated ghrelin levels. The hepatic GH effector IGF-1 levels are not correspondingly increased in conditions with high endogenous plasma ghrelin levels, such as ghrelin-producing tumours (<xref ref-type="other" rid="bib8">Corbetta <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib57">Tsolakis <italic>et al</italic>, 2004</xref>). Furthermore, the administration of ghrelin does not significantly affect the IGF-1 level in healthy volunteers (<xref ref-type="other" rid="bib17">Enomoto <italic>et al</italic>, 2003</xref>), patients with cardiovascular (<xref ref-type="other" rid="bib45">Nagaya <italic>et al</italic>, 2004</xref>) or pulmonary diseases (<xref ref-type="other" rid="bib42">Nagaya <italic>et al</italic>, 2005</xref>), tumour-bearing animals (<xref ref-type="other" rid="bib10">DeBoer <italic>et al</italic>, 2007</xref>), or our patients with CACS. In contrast, studies using synthetic oral ghrelin mimetics have shown a significant effect on the IGF-1 level in volunteers and in the frail elderly (<xref ref-type="other" rid="bib52">Smith, 2005</xref>) or patients with cancer cachexia (<xref ref-type="other" rid="bib19">Garcia <italic>et al</italic>, 2007</xref>).</p><p>Higher morning fasting total ghrelin levels 3 days after i.v. ghrelin administration suggest a carryover effect. As the half-life of ghrelin is short &#x02013; approximately 15&#x02009;min &#x02013; a systematic mistake in the analysis was thought likely, but an independent, blinded laboratory confirmed our results. Ghrelin levels were normal before infusion at 1030 hours. Renal function was not impaired. These unexpected findings of total, but not active, ghrelin remain unexplained at present but may indeed be without any physiological significance.</p><p>Our study of patients with far-advanced cancer was not designed to detect effects on nutritional intake, eating-associated symptoms, or lean-body mass. We found no major differences for these efficacy parameters between ghrelin and placebo in preliminary analyses. Our finding contrasts with the data observed in animal models (<xref ref-type="other" rid="bib23">Hanada <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib58">Wang <italic>et al</italic>, 2006</xref>; <xref ref-type="other" rid="bib10">DeBoer <italic>et al</italic>, 2007</xref>). Our methodology with treatment of secondary anorexia, nutritionist-monitored lunch meals, full placebo control of all outcomes, and standardised procedures and time schedules makes systemic errors unlikely.</p><p>In contrast to one recent small series of patients with mainly (5/7) breast cancer (<xref ref-type="other" rid="bib46">Neary <italic>et al</italic>, 2004</xref>), our patients had tumours typically leading to CACS. A high intrapatient variability of symptoms and nutritional intake is reported in patients with advanced, incurable cancer (<xref ref-type="other" rid="bib54">Stromgren <italic>et al</italic>, 2006</xref>). Baseline food intake (<xref ref-type="other" rid="bib21">Gilg and Lutz, 2006</xref>) and dietary patterns with high protein or liquid intake (<xref ref-type="other" rid="bib4">Blom <italic>et al</italic>, 2006</xref>) may influence ghrelin regulation. Drugs for symptom control (eg, haloperidol (<xref ref-type="other" rid="bib28">Jaszberenyi <italic>et al</italic>, 2006</xref>), 5-HT-3 antagonist (<xref ref-type="other" rid="bib11">Depoortere <italic>et al</italic>, 2006</xref>)) may interact with ghrelin metabolism. Patients often have enhanced levels of proinflammatory cytokines and stress, which are reported to increase preprandial activation of ghrelin secretion (<xref ref-type="other" rid="bib31">Kristenssson <italic>et al</italic>, 2006</xref>) by activation of sympathetic nerves but not by epinephrine (<xref ref-type="other" rid="bib40">Mundinger <italic>et al</italic>, 2006</xref>). Alterations in testosterone levels may influence ghrelin regulation, as testosterone treatment in prepubertal boys decreased ghrelin values (<xref ref-type="other" rid="bib33">Lebenthal <italic>et al</italic>, 2006</xref>). Patients may have remaining side effects of prior chemotherapy mediating CACS (<xref ref-type="other" rid="bib26">Hutton <italic>et al</italic>, 2007</xref>).</p><p>Ghrelin may prolong the premature gastric phase III of migrating motor complex tone in the proximal stomach (<xref ref-type="other" rid="bib55">Tack <italic>et al</italic>, 2006</xref>), leading to enhanced gastrointestinal motility without (<xref ref-type="other" rid="bib55">Tack <italic>et al</italic>, 2006</xref>) and with (<xref ref-type="other" rid="bib36">Liu <italic>et al</italic>, 2006</xref>) increased food intake, but some studies show no stimulatory effect of ghrelin on motility (<xref ref-type="other" rid="bib11">Depoortere <italic>et al</italic>, 2006</xref>; <xref ref-type="other" rid="bib47">Ohno <italic>et al</italic>, 2006</xref>). Patients with advanced cancer often have autonomic dysfunction (<xref ref-type="other" rid="bib53">Strasser <italic>et al</italic>, 2006</xref>), as did 83&#x00025; of our patients. We found no differences in autonomic function during or after two single infusions of ghrelin.</p><p>Some of our patients seem to prefer ghrelin to placebo, and this may be associated with the effect of peripheral ghrelin targeting the mesolimbic reward circuitry (<xref ref-type="other" rid="bib1">Abizaid <italic>et al</italic>, 2006</xref>). The limitations of this study design include the lack of chronic efficacy data beyond two weekly infusions; namely, body composition (lean body mass, fat mass (<xref ref-type="other" rid="bib56">Theander-Carrillo <italic>et al</italic>, 2006</xref>)), objective subconscious locomotive motor and physical activity (<xref ref-type="other" rid="bib28">Jaszberenyi <italic>et al</italic>, 2006</xref>), energy expenditure measurements (<xref ref-type="other" rid="bib34">Lejeune <italic>et al</italic>, 2006</xref>), and gastrointestinal motility (<xref ref-type="other" rid="bib3">Binn <italic>et al</italic>, 2006</xref>; <xref ref-type="other" rid="bib4">Blom <italic>et al</italic>, 2006</xref>). Our results on dose responsiveness may be influenced by unbalanced groups: UD patients had more metastases, greater weight loss, lower dietary intake, more early satiety, and were closer to death. However, given the double-crossover design, no effect on outcomes is expected from unequal (4 <italic>vs</italic> 7) randomisation in the UD group.</p><p>The patients in our study represent a very diverse population, since this trial was conducted with more or less unselected patients, with CACS having mostly far advanced cancer, as the median survival documents, and various tumour types. Our main aim was to explore the safety and tolerability of i.v. ghrelin in such a clinical situation, in which the interpretation of (negative) efficacy data requires considerable caution. In the two patients with stomach and oesophageal cancer, the clinical efficacy of ghrelin may be limited, since in patients having had vagotomy ghrelin induced only an increase in GH secretion but not in energy intake (<xref ref-type="other" rid="bib32">le Roux <italic>et al</italic>, 2005</xref>). Given the foreseen clinical application, namely a relatively short interval between intervention and meal but not at the same time (difficult for patients to have continuous infusions during meals or to inject subcutaneously &#x02018;real time' during meals), we chose to offer lunch immediately after, but not during, the ghrelin infusion, and this time difference may explain the lack of difference in energy intake observed between ghrelin and saline. The safety and tolerability data support further exploration of the therapeutic potential of natural ghrelin, namely escalation of dose (<xref ref-type="other" rid="bib58">Wang <italic>et al</italic>, 2006</xref>) and frequency and chronic administration. The patient population may be stratified for baseline ghrelin levels (<xref ref-type="other" rid="bib20">Garcia <italic>et al</italic>, 2005</xref>; <xref ref-type="other" rid="bib60">Wolf <italic>et al</italic>, 2006</xref>), and other factors need to be controlled for, namely genetic alterations of the ghrelin gene (<xref ref-type="other" rid="bib24">Holst and Schwartz, 2006</xref>), cytokine levels (<xref ref-type="other" rid="bib12">Dixit <italic>et al</italic>, 2004</xref>), stress level (<xref ref-type="other" rid="bib31">Kristenssson <italic>et al</italic>, 2006</xref>), hypogonadism (<xref ref-type="other" rid="bib53">Strasser <italic>et al</italic>, 2006</xref>), patients' eating preferences (<xref ref-type="other" rid="bib4">Blom <italic>et al</italic>, 2006</xref>), baseline food intake (<xref ref-type="other" rid="bib21">Gilg and Lutz, 2006</xref>), and gastric emptying (<xref ref-type="other" rid="bib3">Binn <italic>et al</italic>, 2006</xref>). These strategies may counteract the series of many negative cachexia phase III trials (EPA, cannabinoids) or single not confirmed studies (ATP, thalidomide), treating uniformly all patients having loss of weight and appetite, despite promising pathophysiological concepts.</p><p>In conclusion, ghrelin administered intravenously as one therapeutic dose and repeated once after 1 week was safe and well tolerated by both LD and UD patients with far-advanced cancer and anorexia/cachexia. Several patients preferred ghrelin to placebo despite a lack of major differences in food intake or symptoms. The stimulation of GH, reflecting biological activity, was dose-dependent. Anorexia/cachexia remains a burdensome clinical problem with few treatment options. Further research with ghrelin will explore dose escalations, route and schedule modifications, and mechanisms of ghrelin resistance.</p></sec></body><back><ack><p>We thank our patients for engaged participation, the nursing staff of the oncology outpatient unit for invaluable support, and the oncologists who referred patients to the study. Countless technicians, laboratory professionals, and the oncology research unit supported this trial, including Dr S Thammacharoen from the Institute of Veterinary Physiology, Monika Diethelm from the body composition unit, Doris Giselbrecht <italic>et al</italic> from the nutritionist team, Monika Ott from cardiology, Beppi Osterwalder as the independent senior physician performing the unblinding of the database, and the independent radiologists who reviewed all films to judge tumour size and dynamics. Tina Nielsen and Hans Schambye from GastroTech Pharm A/S, Denmark, assisted in data presentation blinded to treatment assignment. Shu-Fang Hsu-Schmitz provided statistical advice. Scientific editing was provided by Susan Eastwood ELS(D). Research support was provided by OncoSuisse OCS &#x02013; 01385 &#x02013; 08 &#x02013; 2003: scientific project grant; Eastern Switzerland Cancer Research Fund: scientific project support; Swiss Institute of Applied Cancer Research: pilot development grant; Gastrotech Pharm A/S, Denmark: unrestricted research support; and Amgen Switzerland: unrestricted grant.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abizaid</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>ZW</given-names></name><name><surname>Andrews</surname><given-names>ZB</given-names></name><name><surname>Shanabrough</surname><given-names>M</given-names></name><name><surname>Borok</surname><given-names>E</given-names></name><name><surname>Elsworth</surname><given-names>JD</given-names></name><name><surname>Roth</surname><given-names>RH</given-names></name><name><surname>Sleeman</surname><given-names>MW</given-names></name><name><surname>Picciotto</surname><given-names>MR</given-names></name><name><surname>Tschop</surname><given-names>MH</given-names></name><name><surname>Gao</surname><given-names>XB</given-names></name><name><surname>Horvath</surname><given-names>TL</given-names></name></person-group><article-title>Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>3229</fpage><lpage>3239</lpage><!--PubMed citation query: 'J Clin Invest||116|3229||bib1|'--><pub-id pub-id-type="pmid">17060947</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akamizu</surname><given-names>T</given-names></name><name><surname>Takaya</surname><given-names>K</given-names></name><name><surname>Irako</surname><given-names>T</given-names></name><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Teramukai</surname><given-names>S</given-names></name><name><surname>Matsuyama</surname><given-names>A</given-names></name><name><surname>Tada</surname><given-names>H</given-names></name><name><surname>Miura</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>A</given-names></name><name><surname>Fukushima</surname><given-names>M</given-names></name><name><surname>Yokode</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects</article-title><source>Eur J Endocrinol</source><year>2004</year><volume>150</volume><fpage>447</fpage><lpage>455</lpage><!--PubMed citation query: 'Eur J Endocrinol||150|447||bib2|'--><pub-id pub-id-type="pmid">15080773</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Binn</surname><given-names>M</given-names></name><name><surname>Albert</surname><given-names>C</given-names></name><name><surname>Gougeon</surname><given-names>A</given-names></name><name><surname>Maerki</surname><given-names>H</given-names></name><name><surname>Coulie</surname><given-names>B</given-names></name><name><surname>Lemoyne</surname><given-names>M</given-names></name><name><surname>Rabasa Lhoret</surname><given-names>R</given-names></name><name><surname>Tomasetto</surname><given-names>C</given-names></name><name><surname>Poitras</surname><given-names>P</given-names></name></person-group><article-title>Ghrelin gastrokinetic action in patients with neurogenic gastroparesis</article-title><source>Peptides</source><year>2006</year><volume>27</volume><fpage>1603</fpage><lpage>1606</lpage><!--PubMed citation query: 'Peptides||27|1603||bib3|'--><pub-id pub-id-type="pmid">16426704</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blom</surname><given-names>WA</given-names></name><name><surname>Lluch</surname><given-names>A</given-names></name><name><surname>Stafleu</surname><given-names>A</given-names></name><name><surname>Vinoy</surname><given-names>S</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Schaafsma</surname><given-names>G</given-names></name><name><surname>Hendriks</surname><given-names>HF</given-names></name></person-group><article-title>Effect of a high-protein breakfast on the postprandial ghrelin response</article-title><source>Am J Clin Nutr</source><year>2006</year><volume>83</volume><fpage>211</fpage><lpage>220</lpage><!--PubMed citation query: 'Am J Clin Nutr||83|211||bib4|'--><pub-id pub-id-type="pmid">16469977</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broglio</surname><given-names>F</given-names></name><name><surname>Gianotti</surname><given-names>L</given-names></name><name><surname>Destefanis</surname><given-names>S</given-names></name><name><surname>Fassino</surname><given-names>S</given-names></name><name><surname>Abbate Daga</surname><given-names>G</given-names></name><name><surname>Mondelli</surname><given-names>V</given-names></name><name><surname>Lanfranco</surname><given-names>F</given-names></name><name><surname>Gottero</surname><given-names>C</given-names></name><name><surname>Gauna</surname><given-names>C</given-names></name><name><surname>Hofland</surname><given-names>L</given-names></name><name><surname>Van der Lely</surname><given-names>AJ</given-names></name><name><surname>Ghigo</surname><given-names>E</given-names></name></person-group><article-title>The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state</article-title><source>Clin Endocrinol (Oxford)</source><year>2004</year><volume>60</volume><fpage>592</fpage><lpage>599</lpage><!--PubMed citation query: 'Clin Endocrinol (Oxford)||60|592||bib5|'--></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bruera</surname><given-names>E</given-names></name><name><surname>Chadwick</surname><given-names>S</given-names></name><name><surname>Cowan</surname><given-names>L</given-names></name><name><surname>Drebit</surname><given-names>D</given-names></name><name><surname>Hanson</surname><given-names>J</given-names></name><name><surname>MacDonald</surname><given-names>N</given-names></name><name><surname>van Konkelenberg</surname><given-names>Y</given-names></name></person-group><article-title>Caloric intake assessment in advanced cancer patients: comparison of three methods</article-title><source>Cancer Treat Rep</source><year>1986</year><volume>70</volume><fpage>981</fpage><lpage>983</lpage><!--PubMed citation query: 'Cancer Treat Rep||70|981||bib6|'--><pub-id pub-id-type="pmid">3731154</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cassoni</surname><given-names>P</given-names></name><name><surname>Allia</surname><given-names>E</given-names></name><name><surname>Marrocco</surname><given-names>T</given-names></name><name><surname>Ghe</surname><given-names>C</given-names></name><name><surname>Ghigo</surname><given-names>E</given-names></name><name><surname>Muccioli</surname><given-names>G</given-names></name><name><surname>Papotti</surname><given-names>M</given-names></name></person-group><article-title>Ghrelin and cortistatin in lung cancer: expression of peptides and related receptors in human primary tumors and <italic>in vitro</italic> effect on the H345 small cell carcinoma cell line</article-title><source>J Endocrinol Invest</source><year>2006</year><volume>29</volume><fpage>781</fpage><lpage>790</lpage><!--PubMed citation query: 'J Endocrinol Invest||29|781||bib7|'--><pub-id pub-id-type="pmid">17114908</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corbetta</surname><given-names>S</given-names></name><name><surname>Peracchi</surname><given-names>M</given-names></name><name><surname>Cappiello</surname><given-names>V</given-names></name><name><surname>Lania</surname><given-names>A</given-names></name><name><surname>Lauri</surname><given-names>E</given-names></name><name><surname>Vago</surname><given-names>L</given-names></name><name><surname>Beck-Peccoz</surname><given-names>P</given-names></name><name><surname>Spada</surname><given-names>A</given-names></name></person-group><article-title>Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma</article-title><source>J Clin Endocrinol Metab</source><year>2003</year><volume>88</volume><fpage>3117</fpage><lpage>3120</lpage><!--PubMed citation query: 'J Clin Endocrinol Metab||88|3117||bib8|'--><pub-id pub-id-type="pmid">12843152</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Date</surname><given-names>Y</given-names></name><name><surname>Murakami</surname><given-names>N</given-names></name><name><surname>Toshinai</surname><given-names>K</given-names></name><name><surname>Matsukura</surname><given-names>S</given-names></name><name><surname>Niijima</surname><given-names>A</given-names></name><name><surname>Matsuo</surname><given-names>H</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name><name><surname>Nakazato</surname><given-names>M</given-names></name></person-group><article-title>The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats</article-title><source>Gastroenterology</source><year>2002</year><volume>123</volume><fpage>1120</fpage><lpage>1128</lpage><!--PubMed citation query: 'Gastroenterology||123|1120||bib9|'--><pub-id pub-id-type="pmid">12360474</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DeBoer</surname><given-names>MD</given-names></name><name><surname>Zhu</surname><given-names>XX</given-names></name><name><surname>Levasseur</surname><given-names>P</given-names></name><name><surname>Meguid</surname><given-names>MM</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Inui</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>JE</given-names></name><name><surname>Halem</surname><given-names>HA</given-names></name><name><surname>Dong</surname><given-names>JZ</given-names></name><name><surname>Datta</surname><given-names>R</given-names></name><name><surname>Culler</surname><given-names>MD</given-names></name><name><surname>Marks</surname><given-names>DL</given-names></name></person-group><article-title>Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia</article-title><source>Endocrinology</source><year>2007</year><volume>148</volume><fpage>3004</fpage><lpage>3012</lpage><!--PubMed citation query: 'Endocrinology||148|3004||bib10|'--><pub-id pub-id-type="pmid">17347304</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Depoortere</surname><given-names>I</given-names></name><name><surname>Thijs</surname><given-names>T</given-names></name><name><surname>Peeters</surname><given-names>T</given-names></name></person-group><article-title>The contractile effect of the ghrelin receptor antagonist, D-Lys3-GHRP-6, in rat fundic strips is mediated through 5-HT receptors</article-title><source>Eur J Pharmacol</source><year>2006</year><volume>537</volume><fpage>160</fpage><lpage>165</lpage><!--PubMed citation query: 'Eur J Pharmacol||537|160||bib11|'--><pub-id pub-id-type="pmid">16631731</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dixit</surname><given-names>VD</given-names></name><name><surname>Schaffer</surname><given-names>EM</given-names></name><name><surname>Pyle</surname><given-names>RS</given-names></name><name><surname>Collins</surname><given-names>GD</given-names></name><name><surname>Sakthivel</surname><given-names>SK</given-names></name><name><surname>Palaniappan</surname><given-names>R</given-names></name><name><surname>Lillard</surname><given-names>JW</given-names><suffix>Jr</suffix></name><name><surname>Taub</surname><given-names>DD</given-names></name></person-group><article-title>Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells</article-title><source>J Clin Invest</source><year>2004</year><volume>114</volume><fpage>57</fpage><lpage>66</lpage><!--PubMed citation query: 'J Clin Invest||114|57||bib12|'--><pub-id pub-id-type="pmid">15232612</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Onghia</surname><given-names>V</given-names></name><name><surname>Leoncini</surname><given-names>R</given-names></name><name><surname>Carli</surname><given-names>R</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Giglioni</surname><given-names>S</given-names></name><name><surname>Sorbellini</surname><given-names>F</given-names></name><name><surname>Marzocca</surname><given-names>G</given-names></name><name><surname>Bernini</surname><given-names>A</given-names></name><name><surname>Campagna</surname><given-names>S</given-names></name><name><surname>Marinello</surname><given-names>E</given-names></name><name><surname>Vannoni</surname><given-names>D</given-names></name></person-group><article-title>Circulating gastrin and ghrelin levels in patients with colorectal cancer: correlation with tumour stage, Helicobacter pylori infection and BMI</article-title><source>Biomed Pharmacother</source><year>2007</year><volume>61</volume><fpage>137</fpage><lpage>141</lpage><!--PubMed citation query: 'Biomed Pharmacother||61|137||bib13|'--><pub-id pub-id-type="pmid">17258885</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Druce</surname><given-names>MR</given-names></name><name><surname>Neary</surname><given-names>NM</given-names></name><name><surname>Small</surname><given-names>CJ</given-names></name><name><surname>Milton</surname><given-names>J</given-names></name><name><surname>Monteiro</surname><given-names>M</given-names></name><name><surname>Patterson</surname><given-names>M</given-names></name><name><surname>Ghatei</surname><given-names>MA</given-names></name><name><surname>Bloom</surname><given-names>SR</given-names></name></person-group><article-title>Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers</article-title><source>Int J Obes (London)</source><year>2006</year><volume>30</volume><fpage>293</fpage><lpage>296</lpage><!--PubMed citation query: 'Int J Obes (London)||30|293||bib14|'--><pub-id pub-id-type="pmid">16247504</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duxbury</surname><given-names>MS</given-names></name><name><surname>Waseem</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>MK</given-names></name><name><surname>Zinner</surname><given-names>MJ</given-names></name><name><surname>Ashley</surname><given-names>SW</given-names></name><name><surname>Whang</surname><given-names>EE</given-names></name></person-group><article-title>Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness</article-title><source>Biochem Biophys Res Commun</source><year>2003</year><volume>309</volume><fpage>464</fpage><lpage>468</lpage><!--PubMed citation query: 'Biochem Biophys Res Commun||309|464||bib15|'--><pub-id pub-id-type="pmid">12951072</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ekeblad</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Lejonklou</surname><given-names>MH</given-names></name><name><surname>Johansson</surname><given-names>T</given-names></name><name><surname>Stalberg</surname><given-names>P</given-names></name><name><surname>Nilsson</surname><given-names>O</given-names></name><name><surname>Ahlman</surname><given-names>H</given-names></name><name><surname>Skogseid</surname><given-names>B</given-names></name></person-group><article-title>Gastrointestinal stromal tumors express the orexigen ghrelin</article-title><source>Endocr Relat Cancer</source><year>2006</year><volume>13</volume><fpage>963</fpage><lpage>970</lpage><!--PubMed citation query: 'Endocr Relat Cancer||13|963||bib16|'--><pub-id pub-id-type="pmid">16954444</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Enomoto</surname><given-names>M</given-names></name><name><surname>Nagaya</surname><given-names>N</given-names></name><name><surname>Uematsu</surname><given-names>M</given-names></name><name><surname>Okumura</surname><given-names>H</given-names></name><name><surname>Nakagawa</surname><given-names>E</given-names></name><name><surname>Ono</surname><given-names>F</given-names></name><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Oya</surname><given-names>H</given-names></name><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Kanmatsuse</surname><given-names>K</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans</article-title><source>Clin Sci (London)</source><year>2003</year><volume>105</volume><fpage>431</fpage><lpage>435</lpage><!--PubMed citation query: 'Clin Sci (London)||105|431||bib17|'--><pub-id pub-id-type="pmid">12773196</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fearon</surname><given-names>KC</given-names></name><name><surname>Voss</surname><given-names>AC</given-names></name><name><surname>Hustead</surname><given-names>DS</given-names></name><collab>Cancer Cachexia Study Group</collab></person-group><article-title>Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis</article-title><source>Am J Clin Nutr</source><year>2006</year><volume>83</volume><fpage>1345</fpage><lpage>1350</lpage><!--PubMed citation query: 'Am J Clin Nutr||83|1345||bib18|'--><pub-id pub-id-type="pmid">16762946</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>J</given-names></name><name><surname>Boccia</surname><given-names>RV</given-names></name><name><surname>Graham</surname><given-names>C</given-names></name><name><surname>Kumor</surname><given-names>K</given-names></name><name><surname>Polvino</surname><given-names>W</given-names></name></person-group><article-title>A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia</article-title><source>J Clin Oncol, 2007 ASCO Annu Meet Proc</source><year>2007</year><volume>25</volume><supplement>Part I</supplement><fpage>9133.22</fpage><!--PubMed citation query: 'J Clin Oncol, 2007 ASCO Annu Meet Proc||25|9133.22||bib19|'--></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>JM</given-names></name><name><surname>Garcia-Touza</surname><given-names>M</given-names></name><name><surname>Hijazi</surname><given-names>RA</given-names></name><name><surname>Taffet</surname><given-names>G</given-names></name><name><surname>Epner</surname><given-names>D</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>RG</given-names></name><name><surname>Cunningham</surname><given-names>GR</given-names></name><name><surname>Marcelli</surname><given-names>M</given-names></name></person-group><article-title>Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>2920</fpage><lpage>2926</lpage><!--PubMed citation query: 'J Clin Endocrinol Metab||90|2920||bib20|'--><pub-id pub-id-type="pmid">15713718</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilg</surname><given-names>S</given-names></name><name><surname>Lutz</surname><given-names>TA</given-names></name></person-group><article-title>The orexigenic effect of peripheral ghrelin differs between rats of different age and with different baseline food intake, and it may in part be mediated by the area postrema</article-title><source>Physiol Behav</source><year>2006</year><volume>87</volume><fpage>353</fpage><lpage>359</lpage><!--PubMed citation query: 'Physiol Behav||87|353||bib21|'--><pub-id pub-id-type="pmid">16356516</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanada</surname><given-names>T</given-names></name><name><surname>Toshinai</surname><given-names>K</given-names></name><name><surname>Date</surname><given-names>Y</given-names></name><name><surname>Kajimura</surname><given-names>N</given-names></name><name><surname>Tsukada</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name><name><surname>Nakazato</surname><given-names>M</given-names></name></person-group><article-title>Upregulation of ghrelin expression in cachectic nude mice bearing human melanoma cells</article-title><source>Metabolism</source><year>2004</year><volume>53</volume><fpage>84</fpage><lpage>88</lpage><!--PubMed citation query: 'Metabolism||53|84||bib22|'--><pub-id pub-id-type="pmid">14681847</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanada</surname><given-names>T</given-names></name><name><surname>Toshinai</surname><given-names>K</given-names></name><name><surname>Kajimura</surname><given-names>N</given-names></name><name><surname>Nara-Ashizawa</surname><given-names>N</given-names></name><name><surname>Tsukada</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Osuye</surname><given-names>K</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name><name><surname>Matsukura</surname><given-names>S</given-names></name><name><surname>Nakazato</surname><given-names>M</given-names></name></person-group><article-title>Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells</article-title><source>Biochem Biophys Res Commun</source><year>2003</year><volume>301</volume><fpage>275</fpage><lpage>279</lpage><!--PubMed citation query: 'Biochem Biophys Res Commun||301|275||bib23|'--><pub-id pub-id-type="pmid">12565855</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holst</surname><given-names>B</given-names></name><name><surname>Schwartz</surname><given-names>TW</given-names></name></person-group><article-title>Ghrelin receptor mutations &#x02013; too little height and too much hunger</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>637</fpage><lpage>641</lpage><!--PubMed citation query: 'J Clin Invest||116|637||bib24|'--><pub-id pub-id-type="pmid">16511600</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Fan</surname><given-names>YZ</given-names></name><name><surname>Ge</surname><given-names>BJ</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Tu</surname><given-names>ZY</given-names></name></person-group><article-title>Circulating ghrelin in patients with gastric or colorectal cancer</article-title><source>Dig Dis Sci</source><year>2007</year><volume>52</volume><fpage>803</fpage><lpage>809</lpage><!--PubMed citation query: 'Dig Dis Sci||52|803||bib25|'--><pub-id pub-id-type="pmid">17245626</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutton</surname><given-names>JL</given-names></name><name><surname>Baracos</surname><given-names>VE</given-names></name><name><surname>Wismer</surname><given-names>WV</given-names></name></person-group><article-title>Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer</article-title><source>J Pain Symptom Manage</source><year>2007</year><volume>33</volume><fpage>156</fpage><lpage>165</lpage><!--PubMed citation query: 'J Pain Symptom Manage||33|156||bib26|'--><pub-id pub-id-type="pmid">17280921</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inui</surname><given-names>A</given-names></name></person-group><article-title>Cancer anorexia&#x02013;cachexia syndrome: current issues in research and management</article-title><source>CA Cancer Clin</source><year>2002</year><volume>52</volume><fpage>72</fpage><lpage>91</lpage><!--PubMed citation query: 'CA Cancer Clin||52|72||bib27|'--></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaszberenyi</surname><given-names>M</given-names></name><name><surname>Bujdoso</surname><given-names>E</given-names></name><name><surname>Bagosi</surname><given-names>Z</given-names></name><name><surname>Telegdy</surname><given-names>G</given-names></name></person-group><article-title>Mediation of the behavioral, endocrine and thermoregulatory actions of ghrelin</article-title><source>Horm Behav</source><year>2006</year><volume>50</volume><fpage>266</fpage><lpage>273</lpage><!--PubMed citation query: 'Horm Behav||50|266||bib28|'--><pub-id pub-id-type="pmid">16643913</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeffery</surname><given-names>PL</given-names></name><name><surname>Murray</surname><given-names>RE</given-names></name><name><surname>Yeh</surname><given-names>AH</given-names></name><name><surname>McNamara</surname><given-names>JF</given-names></name><name><surname>Duncan</surname><given-names>RP</given-names></name><name><surname>Francis</surname><given-names>GD</given-names></name><name><surname>Herington</surname><given-names>AC</given-names></name><name><surname>Chopin</surname><given-names>LK</given-names></name></person-group><article-title>Expression and function of the ghrelin axis, including a novel preproghrelin isoform, in human breast cancer tissues and cell lines</article-title><source>Endocr Relat Cancer</source><year>2005</year><volume>12</volume><fpage>839</fpage><lpage>850</lpage><!--PubMed citation query: 'Endocr Relat Cancer||12|839||bib29|'--><pub-id pub-id-type="pmid">16322325</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Date</surname><given-names>Y</given-names></name><name><surname>Nakazato</surname><given-names>M</given-names></name><name><surname>Matsuo</surname><given-names>H</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Ghrelin is a growth-hormone-releasing acylated peptide from stomach</article-title><source>Nature</source><year>1999</year><volume>402</volume><fpage>656</fpage><lpage>660</lpage><!--PubMed citation query: 'Nature||402|656||bib30|'--><pub-id pub-id-type="pmid">10604470</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kristenssson</surname><given-names>E</given-names></name><name><surname>Sundqvist</surname><given-names>M</given-names></name><name><surname>Astin</surname><given-names>M</given-names></name><name><surname>Kjerling</surname><given-names>M</given-names></name><name><surname>Mattsson</surname><given-names>H</given-names></name><name><surname>Dornonville de la Cour</surname><given-names>C</given-names></name><name><surname>Hakanson</surname><given-names>R</given-names></name><name><surname>Lindstrom</surname><given-names>E</given-names></name></person-group><article-title>Acute psychological stress raises plasma ghrelin in the rat</article-title><source>Regul Pept</source><year>2006</year><volume>134</volume><fpage>114</fpage><lpage>117</lpage><!--PubMed citation query: 'Regul Pept||134|114||bib31|'--><pub-id pub-id-type="pmid">16540188</pub-id></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>le Roux</surname><given-names>CW</given-names></name><name><surname>Neary</surname><given-names>NM</given-names></name><name><surname>Halsey</surname><given-names>TJ</given-names></name><name><surname>Small</surname><given-names>CJ</given-names></name><name><surname>Martinez-Isla</surname><given-names>AM</given-names></name><name><surname>Ghatei</surname><given-names>MA</given-names></name><name><surname>Theodorou</surname><given-names>NA</given-names></name><name><surname>Bloom</surname><given-names>SR</given-names></name></person-group><article-title>Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>4521</fpage><lpage>4524</lpage><!--PubMed citation query: 'J Clin Endocrinol Metab||90|4521||bib32|'--><pub-id pub-id-type="pmid">15914532</pub-id></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lebenthal</surname><given-names>Y</given-names></name><name><surname>Gat-Yablonski</surname><given-names>G</given-names></name><name><surname>Shtaif</surname><given-names>B</given-names></name><name><surname>Padoa</surname><given-names>A</given-names></name><name><surname>Phillip</surname><given-names>M</given-names></name><name><surname>Lazar</surname><given-names>L</given-names></name></person-group><article-title>Effect of sex hormone administration on circulating ghrelin levels in peripubertal children</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>328</fpage><lpage>331</lpage><!--PubMed citation query: 'J Clin Endocrinol Metab||91|328||bib33|'--><pub-id pub-id-type="pmid">16249289</pub-id></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lejeune</surname><given-names>MP</given-names></name><name><surname>Westerterp</surname><given-names>KR</given-names></name><name><surname>Adam</surname><given-names>TC</given-names></name><name><surname>Luscombe-Marsh</surname><given-names>ND</given-names></name><name><surname>Westerterp-Plantenga</surname><given-names>MS</given-names></name></person-group><article-title>Ghrelin and glucagon-like peptide 1 concentrations, 24-h satiety, and energy and substrate metabolism during a high-protein diet and measured in a respiration chamber</article-title><source>Am J Clin Nutr</source><year>2006</year><volume>83</volume><fpage>89</fpage><lpage>94</lpage><!--PubMed citation query: 'Am J Clin Nutr||83|89||bib34|'--><pub-id pub-id-type="pmid">16400055</pub-id></citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>F</given-names></name><name><surname>Edholm</surname><given-names>T</given-names></name><name><surname>Schmidt</surname><given-names>PT</given-names></name><name><surname>Gryback</surname><given-names>P</given-names></name><name><surname>Jacobsson</surname><given-names>H</given-names></name><name><surname>Degerblad</surname><given-names>M</given-names></name><name><surname>Hoybye</surname><given-names>C</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Rehfeld</surname><given-names>JF</given-names></name><name><surname>Hellstrom</surname><given-names>PM</given-names></name><name><surname>Naslund</surname><given-names>E</given-names></name></person-group><article-title>Ghrelin stimulates gastric emptying and hunger in normal-weight humans</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>3296</fpage><lpage>3302</lpage><!--PubMed citation query: 'J Clin Endocrinol Metab||91|3296||bib35|'--><pub-id pub-id-type="pmid">16772353</pub-id></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YL</given-names></name><name><surname>Malik</surname><given-names>NM</given-names></name><name><surname>Sanger</surname><given-names>GJ</given-names></name><name><surname>Andrews</surname><given-names>PL</given-names></name></person-group><article-title>Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents</article-title><source>Cancer Chemother Pharmacol</source><year>2006</year><volume>58</volume><fpage>326</fpage><lpage>333</lpage><!--PubMed citation query: 'Cancer Chemother Pharmacol||58|326||bib36|'--><pub-id pub-id-type="pmid">16435157</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mellemkjaer</surname><given-names>L</given-names></name><name><surname>Emborg</surname><given-names>C</given-names></name><name><surname>Gridley</surname><given-names>G</given-names></name><name><surname>Munk-Jorgensen</surname><given-names>P</given-names></name><name><surname>Johansen</surname><given-names>C</given-names></name><name><surname>Tjonneland</surname><given-names>A</given-names></name><name><surname>Kjaer</surname><given-names>SK</given-names></name><name><surname>Olsen</surname><given-names>JH</given-names></name></person-group><article-title>Anorexia nervosa and cancer risk</article-title><source>Cancer Causes Control</source><year>2001</year><volume>12</volume><fpage>173</fpage><lpage>177</lpage><!--PubMed citation query: 'Cancer Causes Control||12|173||bib37|'--><pub-id pub-id-type="pmid">11246846</pub-id></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miljic</surname><given-names>D</given-names></name><name><surname>Pekic</surname><given-names>S</given-names></name><name><surname>Djurovic</surname><given-names>M</given-names></name><name><surname>Doknic</surname><given-names>M</given-names></name><name><surname>Milic</surname><given-names>N</given-names></name><name><surname>Casanueva</surname><given-names>FF</given-names></name><name><surname>Ghatei</surname><given-names>M</given-names></name><name><surname>Popovic</surname><given-names>V</given-names></name></person-group><article-title>Ghrelin has partial or no effect on appetite, growth hormone, prolactin, and cortisol release in patients with anorexia nervosa</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>1491</fpage><lpage>1495</lpage><!--PubMed citation query: 'J Clin Endocrinol Metab||91|1491||bib38|'--><pub-id pub-id-type="pmid">16449333</pub-id></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mottershead</surname><given-names>M</given-names></name><name><surname>Karteris</surname><given-names>E</given-names></name><name><surname>Barclay</surname><given-names>JY</given-names></name><name><surname>Suortamo</surname><given-names>S</given-names></name><name><surname>Newbold</surname><given-names>M</given-names></name><name><surname>Randeva</surname><given-names>H</given-names></name><name><surname>Nwokolo</surname><given-names>CU</given-names></name></person-group><article-title>Immunohistochemical and quantitative mRNA assessment of ghrelin expression in gastric and oesophageal adenocarcinoma</article-title><source>J Clin Pathol</source><year>2007</year><volume>60</volume><fpage>405</fpage><lpage>409</lpage><!--PubMed citation query: 'J Clin Pathol||60|405||bib39|'--><pub-id pub-id-type="pmid">16751299</pub-id></citation></ref><ref id="bib40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mundinger</surname><given-names>TO</given-names></name><name><surname>Cummings</surname><given-names>DE</given-names></name><name><surname>Taborsky</surname><given-names>GJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Direct stimulation of ghrelin secretion by sympathetic nerves</article-title><source>Endocrinology</source><year>2006</year><volume>147</volume><fpage>2893</fpage><lpage>2901</lpage><!--PubMed citation query: 'Endocrinology||147|2893||bib40|'--><pub-id pub-id-type="pmid">16527847</pub-id></citation></ref><ref id="bib41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CD</given-names></name><name><surname>Martin</surname><given-names>NM</given-names></name><name><surname>Patterson</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>SA</given-names></name><name><surname>Ghatei</surname><given-names>MA</given-names></name><name><surname>Kamm</surname><given-names>MA</given-names></name><name><surname>Johnston</surname><given-names>C</given-names></name><name><surname>Bloom</surname><given-names>SR</given-names></name><name><surname>Emmanuel</surname><given-names>AV</given-names></name></person-group><article-title>Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study</article-title><source>Gut</source><year>2005</year><volume>54</volume><fpage>1693</fpage><lpage>1698</lpage><!--PubMed citation query: 'Gut||54|1693||bib41|'--><pub-id pub-id-type="pmid">16085693</pub-id></citation></ref><ref id="bib42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagaya</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>S</given-names></name><name><surname>Oya</surname><given-names>H</given-names></name><name><surname>Uematsu</surname><given-names>M</given-names></name><name><surname>Miyatake</surname><given-names>K</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Treatment of cachexia with ghrelin in patients with COPD</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>1187</fpage><lpage>1193</lpage><!--PubMed citation query: 'Chest||128|1187||bib42|'--><pub-id pub-id-type="pmid">16162705</pub-id></citation></ref><ref id="bib43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagaya</surname><given-names>N</given-names></name><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Uematsu</surname><given-names>M</given-names></name><name><surname>Yamagishi</surname><given-names>M</given-names></name><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Oya</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Hemodynamic and hormonal effects of human ghrelin in healthy volunteers</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2001a</year><volume>280</volume><fpage>R1483</fpage><lpage>R1487</lpage><!--PubMed citation query: 'Am J Physiol Regul Integr Comp Physiol||280|R1483||bib43|'--><pub-id pub-id-type="pmid">11294772</pub-id></citation></ref><ref id="bib44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagaya</surname><given-names>N</given-names></name><name><surname>Miyatake</surname><given-names>K</given-names></name><name><surname>Uematsu</surname><given-names>M</given-names></name><name><surname>Oya</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>W</given-names></name><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Nakanishi</surname><given-names>N</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure</article-title><source>J Clin Endocrinol Metab</source><year>2001b</year><volume>86</volume><fpage>5854</fpage><lpage>5859</lpage><!--PubMed citation query: 'J Clin Endocrinol Metab||86|5854||bib44|'--><pub-id pub-id-type="pmid">11739451</pub-id></citation></ref><ref id="bib45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagaya</surname><given-names>N</given-names></name><name><surname>Moriya</surname><given-names>J</given-names></name><name><surname>Yasumura</surname><given-names>Y</given-names></name><name><surname>Uematsu</surname><given-names>M</given-names></name><name><surname>Ono</surname><given-names>F</given-names></name><name><surname>Shimizu</surname><given-names>W</given-names></name><name><surname>Ueno</surname><given-names>K</given-names></name><name><surname>Kitakaze</surname><given-names>M</given-names></name><name><surname>Miyatake</surname><given-names>K</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>3674</fpage><lpage>3679</lpage><!--PubMed citation query: 'Circulation||110|3674||bib45|'--><pub-id pub-id-type="pmid">15569841</pub-id></citation></ref><ref id="bib46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neary</surname><given-names>NM</given-names></name><name><surname>Small</surname><given-names>CJ</given-names></name><name><surname>Wren</surname><given-names>AM</given-names></name><name><surname>Lee</surname><given-names>JL</given-names></name><name><surname>Druce</surname><given-names>MR</given-names></name><name><surname>Palmieri</surname><given-names>C</given-names></name><name><surname>Frost</surname><given-names>GS</given-names></name><name><surname>Ghatei</surname><given-names>MA</given-names></name><name><surname>Coombes</surname><given-names>RC</given-names></name><name><surname>Bloom</surname><given-names>SR</given-names></name></person-group><article-title>Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>2832</fpage><lpage>2836</lpage><!--PubMed citation query: 'J Clin Endocrinol Metab||89|2832||bib46|'--><pub-id pub-id-type="pmid">15181065</pub-id></citation></ref><ref id="bib47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohno</surname><given-names>T</given-names></name><name><surname>Kamiyama</surname><given-names>Y</given-names></name><name><surname>Aihara</surname><given-names>R</given-names></name><name><surname>Nakabayashi</surname><given-names>T</given-names></name><name><surname>Mochiki</surname><given-names>E</given-names></name><name><surname>Asao</surname><given-names>T</given-names></name><name><surname>Kuwano</surname><given-names>H</given-names></name></person-group><article-title>Ghrelin does not stimulate gastrointestinal motility and gastric emptying: an experimental study of conscious dogs</article-title><source>Neurogastroenterol Motil</source><year>2006</year><volume>18</volume><fpage>129</fpage><lpage>135</lpage><!--PubMed citation query: 'Neurogastroenterol Motil||18|129||bib47|'--><pub-id pub-id-type="pmid">16420291</pub-id></citation></ref><ref id="bib48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Omlin</surname><given-names>AG</given-names></name><name><surname>Strasser</surname><given-names>F</given-names></name></person-group><article-title>Secondary causes of cancer-related anorexia: recognition in daily practice by a novel checklist, a pilot study</article-title><source>J Clin Oncol, 2007 ASCO Annu Meet Proc</source><year>2007</year><volume>25</volume><supplement>Part I</supplement><fpage>9058</fpage><!--PubMed citation query: 'J Clin Oncol, 2007 ASCO Annu Meet Proc||25|9058||bib48|'--></citation></ref><ref id="bib49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rudd</surname><given-names>JA</given-names></name><name><surname>Ngan</surname><given-names>MP</given-names></name><name><surname>Wai</surname><given-names>MK</given-names></name><name><surname>King</surname><given-names>AG</given-names></name><name><surname>Witherington</surname><given-names>J</given-names></name><name><surname>Andrews</surname><given-names>PL</given-names></name><name><surname>Sanger</surname><given-names>GJ</given-names></name></person-group><article-title>Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin</article-title><source>Neurosci Lett</source><year>2006</year><volume>392</volume><fpage>79</fpage><lpage>83</lpage><!--PubMed citation query: 'Neurosci Lett||392|79||bib49|'--><pub-id pub-id-type="pmid">16182445</pub-id></citation></ref><ref id="bib50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>DA</given-names></name><name><surname>Held</surname><given-names>K</given-names></name><name><surname>Ising</surname><given-names>M</given-names></name><name><surname>Uhr</surname><given-names>M</given-names></name><name><surname>Weikel</surname><given-names>JC</given-names></name><name><surname>Steiger</surname><given-names>A</given-names></name></person-group><article-title>Ghrelin stimulates appetite, imagination of food, GH, ACTH, and cortisol, but does not affect leptin in normal controls</article-title><source>Neuropsychopharmacology</source><year>2005</year><volume>30</volume><fpage>1187</fpage><lpage>1192</lpage><!--PubMed citation query: 'Neuropsychopharmacology||30|1187||bib50|'--><pub-id pub-id-type="pmid">15688086</pub-id></citation></ref><ref id="bib51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Nagaya</surname><given-names>N</given-names></name><name><surname>Isobe</surname><given-names>T</given-names></name><name><surname>Imazu</surname><given-names>M</given-names></name><name><surname>Okumura</surname><given-names>H</given-names></name><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name><name><surname>Kohno</surname><given-names>N</given-names></name></person-group><article-title>Increased plasma ghrelin level in lung cancer cachexia</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>774</fpage><lpage>778</lpage><!--PubMed citation query: 'Clin Cancer Res||9|774||bib51|'--><pub-id pub-id-type="pmid">12576449</pub-id></citation></ref><ref id="bib52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RG</given-names></name></person-group><article-title>Development of growth hormone secretagogues</article-title><source>Endocr Rev</source><year>2005</year><volume>26</volume><fpage>346</fpage><lpage>360</lpage><!--PubMed citation query: 'Endocr Rev||26|346||bib52|'--><pub-id pub-id-type="pmid">15814848</pub-id></citation></ref><ref id="bib53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strasser</surname><given-names>F</given-names></name><name><surname>Palmer</surname><given-names>JL</given-names></name><name><surname>Schover</surname><given-names>LR</given-names></name><name><surname>Yusuf</surname><given-names>SW</given-names></name><name><surname>Pisters</surname><given-names>K</given-names></name><name><surname>Vassilopoulou-Sellin</surname><given-names>R</given-names></name><name><surname>DeGracia</surname><given-names>B</given-names></name><name><surname>Willey</surname><given-names>JS</given-names></name><name><surname>Bruera</surname><given-names>E</given-names></name></person-group><article-title>The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study</article-title><source>Cancer</source><year>2006</year><volume>107</volume><fpage>2949</fpage><lpage>2957</lpage><!--PubMed citation query: 'Cancer||107|2949||bib53|'--><pub-id pub-id-type="pmid">17103445</pub-id></citation></ref><ref id="bib54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stromgren</surname><given-names>AS</given-names></name><name><surname>Sjogren</surname><given-names>P</given-names></name><name><surname>Goldschmidt</surname><given-names>D</given-names></name><name><surname>Petersen</surname><given-names>MA</given-names></name><name><surname>Pedersen</surname><given-names>L</given-names></name><name><surname>Groenvold</surname><given-names>M</given-names></name></person-group><article-title>Symptom priority and course of symptomatology in specialized palliative care</article-title><source>J Pain Symptom Manage</source><year>2006</year><volume>31</volume><fpage>199</fpage><lpage>206</lpage><!--PubMed citation query: 'J Pain Symptom Manage||31|199||bib54|'--><pub-id pub-id-type="pmid">16563314</pub-id></citation></ref><ref id="bib55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tack</surname><given-names>J</given-names></name><name><surname>Depoortere</surname><given-names>I</given-names></name><name><surname>Bisschops</surname><given-names>R</given-names></name><name><surname>Delporte</surname><given-names>C</given-names></name><name><surname>Coulie</surname><given-names>B</given-names></name><name><surname>Meulemans</surname><given-names>A</given-names></name><name><surname>Janssens</surname><given-names>J</given-names></name><name><surname>Peeters</surname><given-names>T</given-names></name></person-group><article-title>Influence of ghrelin on interdigestive gastrointestinal motility in humans</article-title><source>Gut</source><year>2006</year><volume>55</volume><fpage>327</fpage><lpage>333</lpage><!--PubMed citation query: 'Gut||55|327||bib55|'--><pub-id pub-id-type="pmid">16216827</pub-id></citation></ref><ref id="bib56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theander-Carrillo</surname><given-names>C</given-names></name><name><surname>Wiedmer</surname><given-names>P</given-names></name><name><surname>Cettour-Rose</surname><given-names>P</given-names></name><name><surname>Nogueiras</surname><given-names>R</given-names></name><name><surname>Perez-Tilve</surname><given-names>D</given-names></name><name><surname>Pfluger</surname><given-names>P</given-names></name><name><surname>Castaneda</surname><given-names>TR</given-names></name><name><surname>Muzzin</surname><given-names>P</given-names></name><name><surname>Schurmann</surname><given-names>A</given-names></name><name><surname>Szanto</surname><given-names>I</given-names></name><name><surname>Tschop</surname><given-names>MH</given-names></name><name><surname>Rohner-Jeanrenaud</surname><given-names>F</given-names></name></person-group><article-title>Ghrelin action in the brain controls adipocyte metabolism</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>1983</fpage><lpage>1993</lpage><!--PubMed citation query: 'J Clin Invest||116|1983||bib56|'--><pub-id pub-id-type="pmid">16767221</pub-id></citation></ref><ref id="bib57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsolakis</surname><given-names>AV</given-names></name><name><surname>Portela-Gomes</surname><given-names>GM</given-names></name><name><surname>Stridsberg</surname><given-names>M</given-names></name><name><surname>Grimelius</surname><given-names>L</given-names></name><name><surname>Sundin</surname><given-names>A</given-names></name><name><surname>Eriksson</surname><given-names>BK</given-names></name><name><surname>Oberg</surname><given-names>KE</given-names></name><name><surname>Janson</surname><given-names>ET</given-names></name></person-group><article-title>Malignant gastric ghrelinoma with hyperghrelinemia</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>3739</fpage><lpage>3744</lpage><!--PubMed citation query: 'J Clin Endocrinol Metab||89|3739||bib57|'--><pub-id pub-id-type="pmid">15292299</pub-id></citation></ref><ref id="bib58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name><name><surname>Iresjo</surname><given-names>BM</given-names></name><name><surname>Lonnroth</surname><given-names>C</given-names></name><name><surname>Lundholm</surname><given-names>K</given-names></name></person-group><article-title>Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia</article-title><source>Int J Oncol</source><year>2006</year><volume>28</volume><fpage>1393</fpage><lpage>1400</lpage><!--PubMed citation query: 'Int J Oncol||28|1393||bib58|'--><pub-id pub-id-type="pmid">16685441</pub-id></citation></ref><ref id="bib59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Reed</surname><given-names>J</given-names></name><name><surname>Ceci</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>HQ</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Englander</surname><given-names>EW</given-names></name><name><surname>Greeley</surname><given-names>GH</given-names><suffix>Jr</suffix></name></person-group><article-title>Effect of chronic hyperghrelinemia on ingestive action of ghrelin</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2006</year><volume>290</volume><fpage>R803</fpage><lpage>R808</lpage><!--PubMed citation query: 'Am J Physiol Regul Integr Comp Physiol||290|R803||bib59|'--><pub-id pub-id-type="pmid">16210421</pub-id></citation></ref><ref id="bib60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>I</given-names></name><name><surname>Sadetzki</surname><given-names>S</given-names></name><name><surname>Kanety</surname><given-names>H</given-names></name><name><surname>Kundel</surname><given-names>Y</given-names></name><name><surname>Pariente</surname><given-names>C</given-names></name><name><surname>Epstein</surname><given-names>N</given-names></name><name><surname>Oberman</surname><given-names>B</given-names></name><name><surname>Catane</surname><given-names>R</given-names></name><name><surname>Kaufman</surname><given-names>B</given-names></name><name><surname>Shimon</surname><given-names>I</given-names></name></person-group><article-title>Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients</article-title><source>Cancer</source><year>2006</year><volume>106</volume><fpage>966</fpage><lpage>973</lpage><!--PubMed citation query: 'Cancer||106|966||bib60|'--><pub-id pub-id-type="pmid">16411208</pub-id></citation></ref><ref id="bib61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wren</surname><given-names>AM</given-names></name><name><surname>Seal</surname><given-names>LJ</given-names></name><name><surname>Cohen</surname><given-names>MA</given-names></name><name><surname>Brynes</surname><given-names>AE</given-names></name><name><surname>Frost</surname><given-names>GS</given-names></name><name><surname>Murphy</surname><given-names>KG</given-names></name><name><surname>Dhillo</surname><given-names>WS</given-names></name><name><surname>Ghatei</surname><given-names>MA</given-names></name><name><surname>Bloom</surname><given-names>SR</given-names></name></person-group><article-title>Ghrelin enhances appetite and increases food intake in humans</article-title><source>J Clin Endocrinol Metab</source><year>2001</year><volume>86</volume><fpage>5992</fpage><!--PubMed citation query: 'J Clin Endocrinol Metab||86|5992||bib61|'--><pub-id pub-id-type="pmid">11739476</pub-id></citation></ref><ref id="bib62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yavuzsen</surname><given-names>T</given-names></name><name><surname>Davis</surname><given-names>MP</given-names></name><name><surname>Walsh</surname><given-names>D</given-names></name><name><surname>LeGrand</surname><given-names>S</given-names></name><name><surname>Lagman</surname><given-names>R</given-names></name></person-group><article-title>Systematic review of the treatment of cancer-associated anorexia and weight loss</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>8500</fpage><lpage>8511</lpage><!--PubMed citation query: 'J Clin Oncol||23|8500||bib62|'--><pub-id pub-id-type="pmid">16293879</pub-id></citation></ref><ref id="bib63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>AH</given-names></name><name><surname>Jeffery</surname><given-names>PL</given-names></name><name><surname>Duncan</surname><given-names>RP</given-names></name><name><surname>Herington</surname><given-names>AC</given-names></name><name><surname>Chopin</surname><given-names>LK</given-names></name></person-group><article-title>Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>8295</fpage><lpage>8303</lpage><!--PubMed citation query: 'Clin Cancer Res||11|8295||bib63|'--><pub-id pub-id-type="pmid">16322288</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Flow of patients in a randomised, placebo-controlled, double-blind, double-crossover trial of i.v. ghrelin for cancer-related anorexia/cachexia.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="eps" xlink:href="6604148f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Pharmacokinetics of active and total ghrelin of the upper dose patients. BL, baseline; I-V, blood samples week 1 (I: morning fasting; II: immediately before ghrelin infusion (1030); III: during ghrelin infusion; IV: after ghrelin infusion (1130); V: after lunch (1230)); Ia-Va, blood samples week 2; EOS, end of study. <italic>P</italic>&#x0003c;0.001 for differences of morning fasting level of total ghrelin 3 days after ghrelin or placebo.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="eps" xlink:href="6604148f2"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Demographics of 21 patients with cancer-related anorexia/cachexia</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>Lower-dose group (<italic>n</italic>=9)</bold></th><th align="center" valign="top" charoff="50"><bold>Upper-dose group (<italic>n</italic>=11)</bold></th></tr></thead><tbody valign="top"><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Age (years)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">66 (45, 73)</td><td align="center" valign="top" charoff="50">70 (45, 80)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Gender</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female/male</td><td align="center" valign="top" charoff="50">1/8</td><td align="center" valign="top" charoff="50">2/9</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Diagnosis</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Pancreatic cancer</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Mesothelioma</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Prostate cancer</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Colorectal cancer</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Stomach/esophageal cancer</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;NSCLC</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Urogenital cancer</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Cholangiocarcinoma</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Metastasis (all patients &#x02a7e;1; none CNS)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Liver</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">6</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lung</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Bone</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">6</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Peritoneal</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lymph node</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">8</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Survival time (days)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">233 (14, 436)</td><td align="center" valign="top" charoff="50">67 (16, 386)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Prior chemotherapy (number of regimens)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3&#x02013;5</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Prior radiation therapy</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">5</td></tr><tr><td align="left" valign="top" charoff="50">Prior hormonal therapy</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Weight (kg)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">59 (54, 95)</td><td align="center" valign="top" charoff="50">54 (44, 77)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Body mass index (kg&#x02009;m</italic><sup>&#x02212;<italic>2</italic></sup>)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">21.7 (15.7, 30)</td><td align="center" valign="top" charoff="50">20.6 (17.3, 30.4)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Weight loss last 2 months</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">3.6 (2.2, 15.1)</td><td align="center" valign="top" charoff="50">6.0 (3.6, 11.5)<sup>a</sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Nutritional intake at lunch (kcal)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">650 (144, 1133)</td><td align="center" valign="top" charoff="50">304 (179, 700)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Nutritional intake, whole day (kcal)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">1237 (222, 1864)</td><td align="center" valign="top" charoff="50">889 (179, 1876)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Appetite (0</italic>=<italic>best, 10</italic>=<italic>worst)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">60 (7, 80)</td><td align="center" valign="top" charoff="50">71 (14, 89)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Early satiety (0</italic>=<italic>no, 10</italic>=<italic>worst)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">25 (2, 79)</td><td align="center" valign="top" charoff="50">52 (10, 95)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Heart rate before 1st infusion (BPM)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">90 (50, 103)</td><td align="center" valign="top" charoff="50">83 (54, 120)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>C-reactive protein (mg&#x02009;ml</italic><sup>&#x02212;<italic>1</italic></sup>)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">25 (2, 178)</td><td align="center" valign="top" charoff="50">24 (3, 145)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Free testosterone (pmol&#x02009;l</italic><sup>&#x02212;<italic>1</italic></sup>)<sup>b</sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">22.4 (2.3, 170)</td><td align="center" valign="top" charoff="50">12.6 (&#x0003c;0.5, 25)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Ghrelin, total (pg&#x02009;ml</italic><sup>&#x02212;<italic>1</italic></sup>)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">1041 (317, 1416)</td><td align="center" valign="top" charoff="50">1015 (533, 2598)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Ghrelin, active (pg&#x02009;ml</italic><sup>&#x02212;<italic>1</italic></sup>)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">121 (24, 322)</td><td align="center" valign="top" charoff="50">102 (11, 250)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Leptin (ng&#x02009;ml</italic><sup>&#x02212;<italic>1</italic></sup>)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">0.8 (0.4, 6.4)</td><td align="center" valign="top" charoff="50">1.9 (0.3, 7.4)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Growth hormone (pg&#x02009;ml</italic><sup>&#x02212;<italic>1</italic></sup>)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">1.2 (0.3, 4.9)</td><td align="center" valign="top" charoff="50">1 (0.3, 3.8)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>IGF-1 (pg per 100&#x02009;&#x003bc;l)</italic><sup>c</sup></td></tr><tr><td align="left" valign="top" charoff="50">Median (min, max)</td><td align="center" valign="top" charoff="50">3968 (808, 9143)</td><td align="center" valign="top" charoff="50">1820 (1121, 3675)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Plasma glucose (mmol&#x02009;l</italic><sup>&#x02212;<italic>1</italic></sup>)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (min, max)</td><td align="center" valign="top" charoff="50">4.8 (4.1, 7.5)</td><td align="center" valign="top" charoff="50">5.6 (4.4, 7.9)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Prior major gastrointestinal surgery</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Gastrectomy</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Whipple procedure</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><label/><p>NSCLC=non-small cell lung cancer; CNS=central nervous system; BPM=beats per minute; IGF-1=insulin-like growth factor 1.</p></fn><fn id="t1-fn2"><label>a</label><p>Two patients had missing data on weight loss 2 months before study entry, but had weight loss 6 months before study entry of 8 and 11.6&#x00025;, respectively.</p></fn><fn id="t1-fn3"><label>b</label><p>Testosterone levels are reported only for men (LD <italic>n</italic>=8, UD <italic>n</italic>=9).</p></fn><fn id="t1-fn4"><label>c</label><p>IGF-1 levels are reported for LD <italic>n</italic>=8 and UD <italic>n</italic>=11.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Adverse events of treatment with intravenous ghrelin in 21 patients with cancer-related anorexia/cachexia</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="2" align="center" valign="top" charoff="50"><bold>Lower-dose group (<italic>n</italic>=9)</bold></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Upper-dose group (<italic>n</italic>=11)</bold></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Adverse events related to study drug (probable or possible, all NCI-CTC grade 1 or 2)</bold></th><th align="center" valign="top" charoff="50"><bold>Ghrelin</bold></th><th align="center" valign="top" charoff="50"><bold>Placebo</bold></th><th align="center" valign="top" charoff="50"><bold>Ghrelin</bold></th><th align="center" valign="top" charoff="50"><bold>Placebo</bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>During infusion on treatment days</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Increased bowel activity<sup>a</sup></td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">5</td><td align="center" valign="top" charoff="50">5</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Abdominal pain</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Dry mouth</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Worsening of pre-existing neuropathy</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Dizziness</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Shortness of breath (overeaten, aspiration)<sup>b</sup></td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Chest pain</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Nausea</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Increased stool frequency</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Sweating</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Asthenia</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Between infusion days</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Abdominal pain</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Apoplectiform deafness</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Diarrhea</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Nausea</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Vomiting<sup>b</sup></td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Constipation</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><label/><p>NCI-CTC=common toxicity criteria (CTC) established by the National Cancer Institute (NCI).</p></fn><fn id="t2-fn2"><label>a</label><p>In five patients both on ghrelin and placebo.</p></fn><fn id="t2-fn3"><label>b</label><p>In one patient both on ghrelin and placebo.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Patients' preference of treatment between placebo and intravenous ghrelin</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="4" align="center" valign="top" charoff="50"><bold>Day 7</bold></th><th colspan="4" align="center" valign="top" charoff="50"><bold>End-of-study</bold></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="2" align="center" valign="top" charoff="50"><bold>Lower dose (<italic>n</italic>=9)</bold></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Upper dose (<italic>n</italic>=11)</bold></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Lower dose (<italic>n</italic>=9)</bold></th><th colspan="2" align="center" valign="top" charoff="50"><bold>Upper dose (<italic>n</italic>=9)</bold></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>G-P<sup>a</sup></bold></th><th align="center" valign="top" charoff="50"><bold>P-G<sup>a</sup></bold></th><th align="center" valign="top" charoff="50"><bold>G-P<sup>a</sup></bold></th><th align="center" valign="top" charoff="50"><bold>P-G<sup>a</sup></bold></th><th align="center" valign="top" charoff="50"><bold>G-P-G-P<sup>a</sup></bold></th><th align="center" valign="top" charoff="50"><bold>P-G-P-G<sup>a</sup></bold></th><th align="center" valign="top" charoff="50"><bold>G-P-G-P<sup>a</sup></bold></th><th align="center" valign="top" charoff="50"><bold>P-G-P-G<sup>a</sup></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Treatment preference (VAS), median (min, max)<sup>b</sup></td><td align="center" valign="top" charoff="50">42 (3, 66)</td><td align="center" valign="top" charoff="50">80 (49, 100)</td><td align="center" valign="top" charoff="50">45 (2, 96)</td><td align="center" valign="top" charoff="50">77 (54, 100)</td><td align="center" valign="top" charoff="50">20 (10, 99)</td><td align="center" valign="top" charoff="50">54 (5, 100)</td><td align="center" valign="top" charoff="50">69 (56, 94)</td><td align="center" valign="top" charoff="50">83 (56, 100)</td></tr><tr><td align="left" valign="top" charoff="50">Preference for ghrelin (cutoff VAS 50),<sup>c</sup> number (&#x00025;)</td><td colspan="2" align="center" valign="top" charoff="50">7 (78&#x00025;)<sup>d</sup></td><td colspan="2" align="center" valign="top" charoff="50">9 (82&#x00025;)<sup>d</sup></td><td colspan="2" align="center" valign="top" charoff="50">6 (67&#x00025;)<sup>d</sup></td><td colspan="2" align="center" valign="top" charoff="50">6 (60&#x00025;)<sup>d</sup></td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><label>a</label><p>Treatment sequence (G=Ghrelin, P=Placebo).</p></fn><fn id="t3-fn2"><label>b</label><p>Visual Analogue Scale (VAS: 0&#x02013;100), low numbers indicate that the patient prefers first (day 7) and third (end-of-study) treatment, high numbers second and fourth treatment, respectively.</p></fn><fn id="t3-fn3"><label>c</label><p>VAS treatment preference score &#x0003c;50 in patients receiving the Ghrelin-Placebo-Ghrelin-Placebo order, 100-VAS score &#x0003e;50 in patients receiving the Placebo-Ghrelin-Placebo-Ghrelin order.</p></fn><fn id="t3-fn4"><label>d</label><p>Exact binominal two-sided tests: 4: <italic>P</italic>=NS, 5: <italic>P</italic>=0.065, 6: <italic>P</italic>=NS.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>


